Medicinal chemists revealed the structures of a dozen clinical candidates during the “First-Time Disclosures” symposium on March 26 at the American Chemical Society Spring 2025 meeting in San ...

SASS-001 is an investigational oral clinical candidate under development by SASS for sleep apnea with a central component. The candidate is a combination of sivopixant, a selective P2X3 receptor ...

At the same time, we are advancing our second key clinical candidate – OATD-02. Currently, dose escalation continues to determine the pharmacologically active dose (PAD) and maximum tolerated ...